Stock Events

Stock Events

Biofrontera 

$0.8635
59
+$0.00+0%Monday 01:06

Statistics

Day High
0.8635
Day Low
0.8635
52W High
1.29
52W Low
0.701
Volume
20
Avg. Volume
-
Mkt Cap
12.83M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 18Expected
Q1 2023
Q3 2025
Q1 2026
Q2 2026
Next
-0.62
-0.43
-0.24
-0.05
Expected EPS
-0.22
Actual EPS
N/A

Financials

-25.26%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
41.71MRevenue
-10.54MNet Income

Analyst Ratings

$3.00Average Price Target
The highest estimate is ⁦3.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BFRI.BOATS. It's not an investment recommendation.
AMD
9
AMD
Apple
8
AAPL
Tesla
8
TSLA
NVIDIA
8
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Davis Select U.S. Equity
DUSA
Mkt Cap0
DUSA Pharmaceuticals, Inc. is a direct competitor in the dermatology space, specifically in photodynamic therapy products, similar to Biofrontera's Ameluz for treating actinic keratosis.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. has a diversified portfolio that includes treatments for various conditions, including skin-related diseases, potentially competing with Biofrontera's dermatological products.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. is a global pharmaceutical company with a broad product line that includes treatments for skin conditions, making it a competitor to Biofrontera.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson offers a wide range of healthcare products, including pharmaceuticals and personal care products for skin health, competing with Biofrontera's dermatological treatments.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie Inc., having acquired Allergan, has strengthened its dermatology portfolio, making it a stronger competitor to Biofrontera in the skin care and treatment market.
Novartis
NVS
Mkt Cap303.67B
Novartis International AG has a significant presence in the dermatology market with products that treat a range of skin conditions, competing with Biofrontera's therapeutic offerings.

About

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
Show More
CEO
ISIN
US09077D2099

Listings

XNAS
US
BFRI
MU
DE
B8FK.MU
MU
DE
AI1.MU
STU
DE
AI10.STU

0 Comments

Share your thoughts

FAQs

What is Biofrontera stock price today?▼
The current price of BFRI.BOATS is $0.86 USD — it has increased by +0% in the past 24 hours. Watch Biofrontera stock price performance more closely on the chart.
What is Biofrontera stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Biofrontera stocks are traded under the ticker BFRI.BOATS.
What is Biofrontera market cap?▼
Today Biofrontera has the market capitalization of 12.83M
When is the next Biofrontera earnings date?▼
Biofrontera is going to release the next earnings report on November 18, 2026.
What were Biofrontera earnings last quarter?▼
BFRI.BOATS earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.11 USD resulting in a +52.38% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Biofrontera revenue for the last year?▼
Biofrontera revenue for the last year amounts to 41.71M USD.
What is Biofrontera net income for the last year?▼
BFRI.BOATS net income for the last year is -10.54M USD.
In which sector is Biofrontera located?▼
Biofrontera operates in the Other sector.
When did Biofrontera complete a stock split?▼
The last stock split for Biofrontera was on July 5, 2023 with a ratio of 1:20.